Peptide Supplements Oligopeptide Drug PNB-0408 Dihexa CAS 1401708-83-5

 Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor  and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.

Dihexa CAS 1401708-83-5 Specifications

]    

Dihexa CAS 1401708-83-5 Uses

Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease.

Description:
Use male gonad hypofunction and implied sperm sterility, hydrogen to methyl intermediate.
Mestanolone  (DHT). The systematic name of mestanolone is: 17β-hydroxy-17α-methylandrost-3-one.It is an orally bioavailable  that is highly while only slightly anabolic. It is incapable of aromatization and is not an agonist of the progesterone receptor.

Use for chronic wasting disease, osteoporosis, severe infection and trauma, burn, etc caused by the negative nitrogen balance, promote the growth of premature infants and immature, etc. The fracture is not easy to heal, hypercholesterolemia and postpartum depression can also be used.


Applications:

1. Mesterolone is an orally applicable  (DHT) derivative. it was used with some success in controlled studies of men suffering from various forms of depression.
2. Mesterolone is a relatively weak and rarely used for replacement therapies.
3. Mesterolone widespread use in bodybuilding primarily for antiestrogenic activity in anabolic stacks but such use has declined after introduction of aromatase inhibitors and SERMs


Specifications:

COA: